Published in Biochem Res Int on October 28, 2010
Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 2.74
Invading one step at a time: the role of invadopodia in tumor metastasis. Oncogene (2013) 1.13
MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer (2013) 1.06
Mechanotransduction and cartilage integrity. Ann N Y Acad Sci (2011) 1.02
Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J (2014) 0.92
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer. PLoS One (2015) 0.90
Matrix metalloproteinase-14 both sheds cell surface neuronal glial antigen 2 (NG2) proteoglycan on macrophages and governs the response to peripheral nerve injury. J Biol Chem (2014) 0.90
Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J Biol Chem (2013) 0.90
Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease. J Pharm Bioallied Sci (2012) 0.90
A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP. Oncogenesis (2013) 0.89
Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities. Open Dent J (2014) 0.83
Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening. Int J Mol Sci (2013) 0.82
O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier. J Med Chem (2013) 0.78
New strategies for targeting matrix metalloproteinases. Matrix Biol (2015) 0.77
Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. PLoS One (2015) 0.77
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression. J Control Release (2017) 0.77
An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget (2015) 0.76
Direct expression of active human tissue inhibitors of metalloproteinases by periplasmic secretion in Escherichia coli. Microb Cell Fact (2017) 0.75
Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8. Mol Ther (2016) 0.75
Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies. Int J Mol Sci (2016) 0.75
Clonal cooperativity in heterogenous cancers. Semin Cell Dev Biol (2016) 0.75
Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer (2017) 0.75
Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis. Oncotarget (2016) 0.75
Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles. Mol Imaging (2017) 0.75
Ovarian Cancer Cell Adhesion/Migration Dynamics on Micro-Structured Laminin Gradients Fabricated by Multiphoton Excited Photochemistry. Bioengineering (Basel) (2015) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 6.40
Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol (2007) 6.15
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell (2003) 4.56
Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem (1997) 3.74
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 3.58
Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol (2001) 3.32
How glycosylphosphatidylinositol-anchored membrane proteins are made. Annu Rev Biochem (1995) 3.25
Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer (2005) 3.19
Tendinopathy--from basic science to treatment. Nat Clin Pract Rheumatol (2008) 3.06
Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem (2001) 3.03
Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem (1996) 3.00
A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev (2006) 2.78
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 2.71
Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet (2003) 2.69
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev (2004) 2.52
Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst (2001) 2.24
Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A (2005) 2.19
Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol (2001) 2.14
Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis (1999) 2.06
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem (1995) 2.01
The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol (2007) 1.90
Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A (2009) 1.84
Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med (2002) 1.81
MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol (2007) 1.78
Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J (2007) 1.74
Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res (1995) 1.72
Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J Biol Chem (2001) 1.69
Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci (2002) 1.69
Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci (2003) 1.68
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain (2003) 1.67
Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett (1996) 1.63
Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res (1997) 1.60
cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem (1995) 1.54
Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase. Mol Biol Cell (2008) 1.54
Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res (1996) 1.53
Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem (1999) 1.52
Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res (2003) 1.50
Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol (2005) 1.49
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer (2005) 1.45
Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer (2000) 1.39
Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry (1997) 1.35
Matrix metalloproteases in head and neck cancer. Head Neck (2006) 1.35
Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer (1994) 1.34
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res (1999) 1.34
MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev (2008) 1.34
Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem (2001) 1.33
Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol (2004) 1.32
Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest (1997) 1.32
Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res (1999) 1.29
Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem (2000) 1.28
Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol (2002) 1.27
Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins. J Neurosci (2006) 1.26
The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res (2006) 1.25
Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Cartilage (2005) 1.24
Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci (1999) 1.23
Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med (2006) 1.21
The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem (2003) 1.20
Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. J Biol Chem (2001) 1.20
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res (2001) 1.19
Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene (2003) 1.17
The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol (2009) 1.17
Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem (1999) 1.17
Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol (2002) 1.15
Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol (2008) 1.14
Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res (2008) 1.14
Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem (2003) 1.13
Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor. Cancer Res (2000) 1.13
Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One (2009) 1.11
High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer (1996) 1.11
Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum (2009) 1.11
The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem (2004) 1.10
Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res (2000) 1.08
Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res (2006) 1.04
Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res (2004) 1.03
Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res (1996) 1.03
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res (2001) 1.02
Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol (2008) 1.02
Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma. Br J Cancer (2000) 1.02
MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties. J Biol Chem (2007) 1.01
Identification of MMP-15 as an anti-apoptotic factor in cancer cells. J Biol Chem (2005) 1.01
Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. Exp Cell Res (2000) 1.00
Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost (1997) 1.00
Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. Biochim Biophys Acta (1997) 0.99
Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Lett (2001) 0.99
Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase. Eur J Biochem (1999) 0.99
Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett (2002) 0.99
The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. Biol Res Nurs (2009) 0.98
Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today (2007) 0.98
Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int (1998) 0.98
Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res (2006) 0.97
Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J Biol Chem (2000) 0.97
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res (2009) 2.03
Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1. J Leukoc Biol (2006) 0.98
Discovery of human antibodies against the C5aR target using phage display technology. J Mol Recognit (2005) 0.82
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia (2007) 0.82
Crystallization and preliminary X-ray analysis of the complexes between a Fab and two forms of human insulin-like growth factor II. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.75